Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Brief Summary: This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.

Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer

Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.


Options:
A: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo
C: Arm Label: olaparib + cediranib; Type: EXPERIMENTAL; Interventions: Drug: olaparib+cediranib combination therapy | Arm Label: durvalumab + olaparib; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + olaparib combination therapy | Arm Label: durvalumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + paclitaxel treatment | Arm Label: durvalumab +chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab +chemotherapy treatment | Intervention Type: DRUG; Name: olaparib+cediranib combination therapy; Assigned to Arm(s): olaparib + cediranib | Intervention Type: DRUG; Name: durvalumab + olaparib combination therapy; Assigned to Arm(s): durvalumab + olaparib | Intervention Type: DRUG; Name: durvalumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + tremelimumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + paclitaxel treatment; Assigned to Arm(s): durvalumab + tremelimumab + paclitaxel | Intervention Type: DRUG; Name: durvalumab +chemotherapy treatment; Assigned to Arm(s): durvalumab +chemotherapy
D: Arm Label: Arm I (platinum-based chemotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Procedure: Computed Tomography, Procedure: Echocardiography Test, Drug: Gemcitabine, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm III (olaparib, cediranib maleate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate)

Answer: B